E7777 in Japanese patients with relapsed/refractory peripheral and cutaneous T-cell lymphoma: A phase 1 study.

about

E7777 in Japanese patients with relapsed/refractory peripheral and cutaneous T-cell lymphoma: A phase 1 study.

Item

http://www.wikidata.org/entity/Q49834009

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh-hant

name

E7777 in Japanese patients wit ...... ell lymphoma: A phase 1 study.

@en

E7777 in Japanese patients wit ...... ell lymphoma: A phase 1 study.

@nl

type

Item

label

E7777 in Japanese patients wit ...... ell lymphoma: A phase 1 study.

@en

E7777 in Japanese patients wit ...... ell lymphoma: A phase 1 study.

@nl

prefLabel

E7777 in Japanese patients wit ...... ell lymphoma: A phase 1 study.

@en

E7777 in Japanese patients wit ...... ell lymphoma: A phase 1 study.

@nl

P1476

E7777 in Japanese patients wit ...... cell lymphoma: A phase I study

@en

P2093

Kensei Tobinai

http://www.w3.org/2001/XMLSchema#string

Kiyoshi Ando

http://www.w3.org/2001/XMLSchema#string

Masayuki Namiki

http://www.w3.org/2001/XMLSchema#string

Michinori Ogura

http://www.w3.org/2001/XMLSchema#string

Tadashi Nakanishi

http://www.w3.org/2001/XMLSchema#string

Toshiki Uchida

http://www.w3.org/2001/XMLSchema#string

P2860

Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma

T-cell Lymphoma Epidemiology: the Known and Unknown.

Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma.

Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study

Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy.

Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study.

Belinostat in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma: Results of the Pivotal Phase II BELIEF (CLN-19) Study.

Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma.

IL-2- and CD25-dependent immunoregulatory mechanisms in the homeostasis of T-cell subsets.

IL-2 immunotoxin denileukin diftitox reduces regulatory T cells and enhances vaccine-mediated T-cell immunity.

P304

794-802

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/CAS.13513

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

109

http://www.w3.org/2001/XMLSchema#string

P50

Ken Ohmachi

Dai Maruyama

P577

2018-02-26T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29363235

http://www.w3.org/2001/XMLSchema#string

P932

5834772

http://www.w3.org/2001/XMLSchema#string